Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review / 감염과화학요법
Infection and Chemotherapy
; : 153-159, 2018.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-721993
Responsible library:
WPRO
ABSTRACT
Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib.
Full text:
Available
Health context:
Neglected Diseases
Health problem:
Diarrhea
/
Neglected Diseases
Database:
WPRIM (Western Pacific)
Main subject:
Protein-Tyrosine Kinases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Ganciclovir
/
Polymerase Chain Reaction
/
Treatment Outcome
/
Colitis
/
Hematologic Neoplasms
/
Cytomegalovirus
/
Diarrhea
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Humans
Language:
English
Journal:
Infection and Chemotherapy
Year:
2018
Document type:
Article